CUTR: AI 评分 46/100 — AI 分析 (4月 2026)

Cutera, Inc. is a medical device company specializing in laser and energy-based aesthetic systems. Their diverse product portfolio caters to various aesthetic treatments, targeting practitioners worldwide.

Key Facts: Price: $0.10 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Cutera, Inc. (CUTR) pioneers advanced aesthetic solutions with its innovative laser and energy-based systems, targeting a growing global market for cosmetic procedures and offering practitioners versatile platforms for diverse dermatological and body sculpting treatments, though profitability remains a key challenge.

CUTR是做什么的？

Cutera, Inc., established in 1988 and headquartered in Brisbane, California, is a global medical device company focused on researching, developing, manufacturing, marketing, and servicing laser and energy-based aesthetic systems. The company's evolution has been marked by a commitment to providing practitioners with cutting-edge technologies for a wide range of aesthetic applications. Cutera's diverse product portfolio includes systems like Secret PRO, which combines fractional CO2 and radio frequency microneedling for skin resurfacing; truSculpt flex, a bio-electrical muscle stimulation device; excel V+, a platform for treating vascular and pigmented lesions; truSculpt iD, for non-surgical body sculpting; and Secret RF, a fractional RF microneedling system. Additionally, Cutera offers the enlighten platform for tattoo removal and treatment of pigmented lesions, excel HR for hair removal, and the xeo platform, a multi-application system for various aesthetic procedures. Beyond devices, Cutera distributes skincare products and provides post-warranty services. The company markets its products through a direct sales force, targeting plastic surgeons, dermatologists, and other qualified practitioners, extending its reach to both medical and non-medical aesthetic practices.

CUTR的投资论点是什么？

Cutera presents a notable market position within the growing aesthetic device market, driven by increasing demand for non-invasive cosmetic procedures. The company's diverse product portfolio, catering to various aesthetic applications, positions it well to capture market share. Key value drivers include the continued adoption of Cutera's innovative platforms like Secret PRO and truSculpt iD, and expansion into new geographic markets. However, the company's current negative profitability, with a profit margin of -76.7%, necessitates careful monitoring and successful execution of its growth strategies. Successful expansion and improved efficiency are crucial for realizing the company's potential and driving shareholder value. Upcoming catalysts include potential regulatory approvals for new applications and strategic partnerships to expand market reach.

CUTR在哪个行业运营？

Cutera operates in the dynamic medical aesthetics industry, which is experiencing growth driven by increasing consumer demand for non-invasive and minimally invasive cosmetic procedures. The market includes various technologies, such as lasers, radiofrequency, and ultrasound, used for skin resurfacing, body contouring, and hair removal. The competitive landscape is characterized by established players and emerging companies, including CMAX, FRES, GMVD, HIND and MTP. Cutera differentiates itself through its comprehensive product portfolio and focus on innovation, but faces competition from companies with greater financial resources and broader market reach. The industry is subject to regulatory oversight and technological advancements, requiring companies to continuously adapt and innovate.

Medical - Devices

Healthcare

CUTR有哪些增长机遇？

Expansion of truSculpt iD: The non-surgical body sculpting market is experiencing significant growth, driven by increasing demand for non-invasive fat reduction and muscle toning solutions. Cutera's truSculpt iD platform is well-positioned to capitalize on this trend. By expanding its marketing efforts and distribution channels, Cutera can increase market share and drive revenue growth in this segment. The global body contouring market is projected to reach $8.5 billion by 2028, presenting a substantial opportunity for Cutera.
Penetration of the Tattoo Removal Market: The tattoo removal market is growing as tattoos become more common and individuals seek removal options. Cutera's enlighten platform offers a solution for tattoo removal, as well as treatment of benign pigmented lesions and acne scars. By focusing on this market, Cutera can diversify its revenue streams and attract new customers. The tattoo removal market is expected to reach $4.8 billion by 2027, offering a significant growth opportunity.
Geographic Expansion into Emerging Markets: Emerging markets, such as Asia-Pacific and Latin America, represent significant growth opportunities for Cutera. These regions are experiencing increasing demand for aesthetic procedures, driven by rising disposable incomes and growing awareness of aesthetic treatments. By expanding its sales and marketing efforts in these regions, Cutera can tap into new customer bases and accelerate revenue growth. This expansion requires strategic partnerships and localized marketing strategies.
Development of New Applications for Existing Platforms: Cutera can leverage its existing technology platforms to develop new applications and treatments, expanding its product offerings and addressing unmet needs in the aesthetic market. For example, the company could explore new applications for its laser and energy-based systems in areas such as skin rejuvenation, scar revision, and acne treatment. This strategy allows Cutera to maximize the return on its existing investments and drive future growth.
Strategic Partnerships and Acquisitions: Cutera can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technology capabilities, and broaden its market reach. By partnering with or acquiring complementary businesses, Cutera can accelerate its growth trajectory and strengthen its competitive position. Potential targets include companies with innovative technologies, established distribution networks, or strong brand recognition in the aesthetic market. These partnerships can provide access to new markets and technologies.

Cutera operates in the medical device industry, specifically focusing on aesthetic laser and energy-based systems.
The company offers a range of products, including Secret PRO, truSculpt flex, excel V+, truSculpt iD, and Secret RF, catering to various aesthetic treatments.
Cutera's products are marketed and sold through a direct sales force to plastic surgeons, dermatologists, and other qualified practitioners.
Cutera has a negative profit margin of -76.7%, indicating significant losses.
The company's gross margin is 19.5%.

CUTR提供哪些产品和服务？

Researches and develops laser and energy-based aesthetic systems.
Manufactures aesthetic systems for practitioners.
Markets aesthetic systems to plastic surgeons, dermatologists, and other qualified practitioners.
Services its installed base of aesthetic systems.
Distributes skincare products.
Offers post-warranty services through extended service contracts or direct billing.

CUTR如何赚钱？

Sells laser and energy-based aesthetic systems to practitioners.
Generates revenue from post-warranty service contracts and direct billing.
Distributes skincare products through its website and sales channels.

Plastic surgeons
Dermatologists
Gynecologists
Family practitioners
Primary care physicians
Physicians performing aesthetic treatments in non-medical offices

Proprietary laser and energy-based technologies.
Established relationships with plastic surgeons and dermatologists.
Comprehensive product portfolio catering to various aesthetic applications.
Service and support infrastructure for installed base of systems.

什么因素可能推动CUTR股价上涨？

Upcoming: Potential regulatory approvals for new applications of existing platforms.
Ongoing: Expansion of sales and marketing efforts in emerging markets.
Ongoing: Development and launch of new aesthetic systems.
Ongoing: Strategic partnerships to expand market reach.

CUTR的主要风险是什么？

Potential: Intense competition from established players with greater financial resources.
Potential: Technological advancements rendering existing products obsolete.
Potential: Regulatory changes impacting the medical device industry.
Ongoing: Negative profit margin and high operating expenses.
Potential: Economic downturn affecting consumer spending on aesthetic procedures.

CUTR的核心优势是什么？

Diverse product portfolio of laser and energy-based aesthetic systems.
Direct sales force targeting key practitioners.
Established presence in the medical aesthetics market.
Ongoing research and development efforts.

CUTR的劣势是什么？

Negative profit margin.
High operating expenses.
Dependence on direct sales force.
Limited brand recognition compared to larger competitors.

CUTR有哪些机遇？

Expansion into emerging markets.
Development of new applications for existing platforms.
Strategic partnerships and acquisitions.
Increasing demand for non-invasive aesthetic procedures.

CUTR面临哪些威胁？

Intense competition from established players.
Technological advancements rendering existing products obsolete.
Regulatory changes impacting the medical device industry.
Economic downturn affecting consumer spending on aesthetic procedures.

CUTR的竞争对手是谁？

Cutera rival 1 — Unknown — (CMAX)
Fresenius Medical Care AG & Co. KGaA — Provides dialysis products and services. — (FRES)
Genmab A/S — Develops antibody therapeutics for cancer. — (GMVD)
Hinduja Global Solutions Limited — Provides business process management services. — (HIND)
Medpace Holdings, Inc. — Clinical contract research organization. — (MTP)

Key Metrics

Price: $0.10 (+0.00%)
Market Cap: $2.0M
MoonshotScore: 46/100

Company Profile

CEO: Taylor C. Harris
Headquarters: Brisbane, CA, US
Employees: 430
Founded: 2004

AI Insight

Stock data pending update.

常见问题

What does Cutera, Inc. do?

Cutera, Inc. is a medical device company that researches, develops, manufactures, markets, and services laser and energy-based aesthetic systems. Their product portfolio includes devices like Secret PRO, truSculpt flex, and excel V+, catering to various aesthetic treatments such as skin resurfacing, body sculpting, and vascular lesion removal. The company sells its products through a direct sales force to plastic surgeons, dermatologists, and other qualified practitioners, providing them with advanced technologies for a wide range of aesthetic procedures. Cutera also distributes skincare products and offers post-warranty services, providing a comprehensive solution for aesthetic practices.

Is CUTR stock a good buy?

Evaluating CUTR stock requires careful consideration of its growth potential and current financial performance. While the company operates in a growing market and has a diverse product portfolio, its negative profit margin of -76.7% raises concerns. Potential investors should assess the company's ability to improve profitability through increased sales, cost reductions, and successful execution of its growth strategies. Upcoming catalysts, such as regulatory approvals and geographic expansion, could drive future growth. However, risks such as intense competition and technological advancements must be considered before making an investment decision.

What are the main risks for CUTR?

Cutera faces several risks, including intense competition from established players in the medical aesthetics market. These competitors may have greater financial resources and broader market reach. Technological advancements could also render Cutera's existing products obsolete, requiring continuous innovation and investment in research and development. Regulatory changes in the medical device industry could impact the company's ability to market and sell its products. Furthermore, Cutera's negative profit margin and high operating expenses pose a significant risk to its financial stability. An economic downturn could also reduce consumer spending on aesthetic procedures, impacting the company's revenue.